semaglutide and parkinson's How a 'blockbuster' treatment for diabetes obesity might slow or stop – Van Andel Institute GLP-1 does not slow Parkinson's
Description
Methods We selected individuals aged 45 years and older already treated with metformin living in Lombardy, Italy, and then split them into two groups if they initiated GLP-1 RAs or other antidiabetic drugs, between 2019 and 2021
Gastrointestinal (GI) adverse eventsparticularly nausea, vomiting, diarrhea, and constipationare the most common side effects, generally emerging during dose escalation and resolving over time
Learn about the results, how it works, when it will be available in the US, and more.
show that glucagon-like peptide-1 receptor agonist reverses transcriptomic aging signatures in mouse glial and neurovascular cells
